Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
E: investor-relations@haleon.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,007.60 | 125.50 | -1.54% |
| CAC 40 | 7,858.83 | 17.53 | -0.22% |
| DAX 40 | 22,390.84 | 149.14 | -0.66% |
| Dow JONES (US) | 42,225.32 | 235.36 | 0.56% |
| FTSE 100 | 8,608.48 | 26.32 | -0.30% |
| HKSE | 23,202.53 | 4.31 | -0.02% |
| NASDAQ | 17,601.05 | 151.16 | 0.87% |
| Nikkei 225 | 34,724.72 | 1,001.15 | -2.80% |
| NZX 50 Index | 12,209.36 | 110.83 | -0.90% |
| S&P 500 | 5,670.97 | 37.90 | 0.67% |
| S&P/ASX 200 | 7,813.50 | 121.00 | -1.52% |
| SSE Composite Index | 3,350.12 | 0.00 | -0.00% |